Prehabilitation in Pancreatic Surgery

In patients with pancreatic cancer, older age, multiple comorbidities, frailty, malnutrition and poor functional status are common, especially in individuals receiving neoadjuvant chemotherapy. These characteristics represent potentially modifiable risk factors for poor postoperative outcomes. The goal of this clinical randomized controlled trial is to evaluate the extent to which a four-week multimodal prehabilitation program impacts on postoperative morbidity, functional and nutritional status and health-related quality of life in patients with localized pancreatic or periampullary cancer scheduled for curative surgery. In addition, the impact of prehabilitation on circulating sarcopenia and cancer cachexia biomarkers in PDAC patients will be explored. Included patients will be randomized (ratio 1:1) and allocated either to the intervention group (Multimodal Prehabilitation), which will receive prehabilitation, or to the control group, which will receive no prehabilitation.

BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer, with 5-year survival around 10%. The combination of surgical resection and chemotherapy represents the most efficacious therapy to improve prognosis for localized PDAC. Patients with pancreatic cancer are generally older adults in whom frailty, sarcopenia and/or malnutrition are common. These features have all been associated with poor postoperative complications and reduced survival. Therefore, the preoperative period and the time window after the end of chemotherapy constitute a unique opportunity to condition modifiable risk factors, improve functional capacity and address deficiencies in physiologic reserves, which might otherwise preclude surgery or significantly impede recovery. Prehabilitation is defined as the process of enhancing patients' functional capacity to enable them to withstand a stressful event. Multimodal prehabilitation, which defines a program including physical, nutritional, and psychological interventions, has shown the most promising results in gastrointestinal cancer surgery. However, no high-quality evidence is currently available for PDAC patients. STUDY OBJECTIVES: Primary Aim: to evaluate if a 4-week multimodal structured prehabilitation program including physical exercise, nutritional and psychological interventions will result in a clinically significant increase in functional capacity, nutritional status and patient-reported health-related quality of life before surgery when compared to a usual care control group, and evaluate the extent to which multimodal prehabilitation impacts on postoperative morbidity and patient recovery compared to usual care. Secondary Aim: to analyze whether multimodal prehabilitation may impact on the concentration and activity of a panel of specific circulating molecules involved in cancer cachexia and skeletal muscle wasting, chronic inflammation. STUDY DESIGN: A randomized controlled trial will be performed in PDAC and periampullary cancer patients with indication to upfront pancreatic resection or pancreatic resection after completion of neoadjuvant chemotherapy. Included patients will be randomized (ratio 1:1) and allocated either to the intervention group (Multimodal Prehabilitation), which will receive prehabilitation, or to the control group, which will receive no prehabilitation. All patients will receive the same intraoperative and postoperative care based on an established enhanced recovery pathway. Inclusion and exclusion criteria as stated in the eligibility section will be assessed and patients consented to participate in the study if they fulfill inclusion criteria. RANDOMIZATION AND BLINDING: The trial is designed as a randomized, controlled, assessor-blind trial. Participants will be randomly assigned to either multimodal prehabilitation or no prehabilitation group with a 1:1 allocation using permuted blocks of random sizes. Randomization will be stratified by neoadjuvant chemotherapy and tumor location (periampullary or pancreatic head-neck cancer versus pancreatic body-tail cancer). Allocation concealment will be ensured as the randomization code will not be released until the patient has been recruited into the trial, which takes place after all baseline measurements have been completed and informed consent has been signed. PREOPERATIVE ASSESSMENT: All patients will be evaluated at baseline (T0) by: * Patient medical history including comorbidities, presence of signs or symptoms, and frailty assessment using Fried's criteria. * Physical performance tests including functional walking capacity (six-minute walk test), timed up and go test, gait speed assessment and handgrip strength test. * Assessment of nutritional status by nutrition history, measurement of anthropometric parameters, completion of nutritional screening questionnaires (MNA, PG-SGA), and standard biochemical markers of malnutrition and inflammation including albumin, prealbumin, total lymphocyte count, and C-reactive protein. * Body composition measurements assessed using two methods: * multi-frequency bioelectrical impedance analysis (BIA) providing data on extracellular and intracellular water as % of total body water, fat mass (FM) as % of body weight, skeletal muscle mass (SK) as % of fat-free mass (FFM) and phase angle (PA°), intramuscular fat mass (IMAT), basal metabolic rate (BMR) energy expenditure and hypotalamic- pituitary- adrenal axis index (HPA); * CT scan image analysis (using preoperative cancer staging and restaging chest and abdomen CT scans) performing automated imaging segmentation using Data Analysis Facilitation Suite (DAFS) by Voronoi Health Analytics, Inc. (https://www.voronoihealthanalytics.com/). * Overall activity of the autonomic nervous system and heart rate variability through photoplethysmography (PPG) stress flow test. This exam allows the study and direct monitoring of all functions of the autonomic nervous system and the related process of biofeedback. * Patient reported outcome questionnaires to measure health related quality of life and patient engagement. The following questionnaires will be administered * Patient reported outcome measurement information system (PROMIS)29+2, a validated questionnaire designed to measure self-reported physical, mental and social health and wellbeing. * Duke activity status index (DASI), a brief questionnaire designed to assess physical function by answering whether they are able to perform 12 listed activities of various intensity (i.e., ambulation, household tasks and leisure activities). * EORTC QLQ C30, a generic core questionnaire that measures health-related quality of life in patients with any cancer. * EORTC QLQ PAN-26, the pancreatic cancer module that supplements the EORTC QLQ-C30. * - Medically unexplained symptoms (MUS) questionnaire investigates the presence of vague symptoms to describe a cluster of manifestations such us chronic fatigue, sleep or appetite disorders, irritable bowel or constipation, tone or mood disorders, non-specific pain syndromes which are sometimes underestimated. * Patient activation measures (PAM)-13, a 13-item questionnaire measuring patients' self-reported knowledge, motivation, and skills for self-management. * Hospital Anxiety and Depression Scale (HADS) questionnaire to measure anxiety and depression. * Blood sample analysis of circulating cytokines, chemokines, interferons, colony stimulating factors, main hormones involved in metabolic homeostasis and cancer cachexia. Four weeks after baseline assessment, on the day before surgery (T1), all patients will repeat all evaluations previously performed at T0. STUDY INTERVENTION Included patients will be randomized (ratio 1:1) and allocated either to the intervention group (Multimodal Prehabilitation), which will receive prehabilitation, or to the control group, which will receive no prehabilitation. Patients in the control group will be treated according to usual standard of care and will be given informative material regarding healthy lifestyle and how to best prepare for surgery. The intervention will consist of a multimodal prehabilitation, a 4-week long preoperative intervention including exercise training, nutritional therapy and anxiety reducing techniques, aimed at preventing or attenuating surgery-driven functional decline as described in the arms and intervention section. VISITS AND FOLLOW-UP: Throughout patient hospital stay, postoperative outcomes including complications, will be recorded. After discharge, patients will be followed-up as routine care by phone calls from a nurse navigator. At 30 days (T2), 60 (T3) and 90 days (T4) after surgery, patient recovery will be re-evaluated during scheduled outpatient visits. Patients will be assessed for: * Functional capacity by the 6MWT and other physical performance tests including TUG, gait speed assessment and handgrip strength test. * Nutritional status by measurement of anthropometric parameters including body weight (kg), height (cm), and body mass index (kg/m2) * Body composition by multi-frequency bioelectrical impedance vector analysis (BIVA) * Health related quality of life through patient reported outcome questionnaires STATISTICAL METHODS: Continuous variables will be summarized using either median and interquartile range (IQR) or mean ± standard deviation (SD), depending on data distribution. Categorical variables will be reported as frequencies and percentages. All analyses will follow the intention-to-treat principle. The between-group difference in the primary outcome will be assessed using a linear regression model after applying a log(+1) transformation to the 90-day Comprehensive Complication Index (CCI®️), adjusting for relevant confounders. Continuous secondary outcomes will be analyzed using appropriate generalized linear models, while binary outcomes will be evaluated using logistic regression to estimate odds ratios (ORs) with 95% confidence intervals (CIs). To account for the repeated measures design, linear mixed-effects models will be employed, incorporating treatment group and time as fixed effects, and patient ID as a random effect. This model will estimate the mean differences in outcomes over time between groups. The effect of the intervention will be reported as adjusted least square mean differences along with corresponding 95% CIs. To minimize attrition bias, missing data will be handled using multiple imputation with chained equations and predictive mean matching. A sensitivity analysis will be conducted to assess the impact of missing data on the primary outcome. A per-protocol analysis will also be performed, including only patients who completed at least 80% of the prehabilitation sessions and excluding those lost to follow-up or who withdrew. A pre-specified subgroup analysis will explore whether the effect of prehabilitation versus standard care on the primary outcome and functional capacity differs across the following patient subgroups: * Frail versus non-frail, defined by Fried Frailty Score Index (FFSI ≥ 2 vs < 2); * Neoadjuvant therapy versus upfront surgery; * Proximal versus distal pancreatectomy; * Elderly versus younger patients, defined as > 75 years vs ≤ 75 years; * Low versus high baseline functional capacity, based on 6-minute walk distance (6MWD < 400 m vs ≥ 400 m) or Duke Activity Status Index (DASI < 34 vs ≥ 34); * High versus low psychological distress, defined by HADS subscale scores (≥ 8 vs < 8); * Nutritional status, defined by PG-SGA scores (< 4 well-nourished, 4-8 moderately malnourished, > 8 severely malnourished); * Sarcopenic versus non-sarcopenic, defined by BIVA-derived ASMMI values (< 7.0 kg/m² in men and < 5.7 kg/m² in women) and CT scan-derived skeletal muscle areas. * Overweight versus non-overweight patients, defined by BMI values (>24.99 kg/m²) Patient satisfaction will be described using means and SDs for continuous variables (or medians and IQRs for skewed distributions) and frequencies and percentages for categorical data. Barriers to adherence among participants who did not meet the 80% session completion threshold will be explored through qualitative interviews, transcribed and categorized according to the COM-B model (Capability, Opportunity, Motivation). Statistical significance will be set at a p-value < 0.05. All analyses will be conducted using STATA® version 18 (StataCorp, College Station, TX, USA). SAMPLE SIZE: The size of the sample was calculated on the basis of the primary aim of the study: the reduction of postoperative complications as determined with the CCI score at 90 days after surgery. In our preliminary data on PDAC surgical population, the mean (SD) CCI is 21.0 (SD 16), and the target reduction is 30%. An alpha of 0.05 and power of 0.80 (two-sided test) was used. Accounting for a 15% of dropout rate, the required sample size was 238 patients, 119 for each arm. ECONOMIC EVALUATIONS: Hospital-related costs will be collected for all patients included in the study over a 90-day postoperative period. These costs include expenses directly associated with patient care, such as the prehabilitation program (staff time, facilities, equipment, and sessions), surgical procedures, length of hospital stay, management of complications, remissions, and follow-up visits within 90 days after surgery. Comparing hospital costs between patients receiving prehabilitation and those undergoing standard care will provide valuable insight into the economic impact of prehabilitation on healthcare resource utilization during the early postoperative period. A cost-utility analysis will be conducted to evaluate the economic value of the prehabilitation program compared to standard care over the 90-day postoperative period. Health-related quality of life (HRQoL) will be assessed using the PROMIS-29+2, which provides the PROPr (Patient-Reported Outcomes Measurement Information System Preference score), a preference-based utility measure derived from PROMIS item responses. These utility values quantify the quality of health on a scale where 0 represents death and 1 represents perfect health. By combining these utility scores with the length of the follow-up period, quality-adjusted life years (QALYs) can be estimated, reflecting both the quantity and quality of life experienced by each patient during this timeframe. This approach allows for capturing the changes in patients' health status due to the intervention or standard care. Hospital costs incurred during the same 90-day period, including all healthcare resource use such as hospital stay, procedures, complications management, and prehabilitation costs, will be integrated into the analysis. The incremental cost-effectiveness ratio (ICER) will then be calculated by dividing the difference in average costs between the two groups by the difference in average QALYs gained. The ICER represents the additional cost required to gain one additional quality-adjusted life year through prehabilitation compared to standard care, providing a summary measure of the intervention's cost-effectiveness.

• Pancreatic Cancer
• Periampullary Cancer
• Frailty Syndrome
• Malnutrition
• Perioperative/Postoperative Complications

• OTHER: Multimodal Prehabilitation

• GR-2021-12374985